| 1358 |
National Cancer Institute |
Html |
en |
Gastrointestinal Complications (PDQ®)–Health Professional Version |
Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed. |
| complete bowel obstruction | 0.653864 |
| stool | 0.625324 |
| gastrointestinal tract | 0.642496 |
| Oncol Nurs Forum | 0.609323 |
| cancer-related diarrhea | 0.733825 |
| refractory diarrhea | 0.683452 |
| diarrhea management | 0.729396 |
| total bowel rest | 0.605453 |
| diarrhea events | 0.682702 |
| bone marrow transplantation | 0.599048 |
| PUBMED Abstract | 0.628255 |
| octreotide acetate | 0.600127 |
| bowel lumen | 0.596911 |
| abdominal pain | 0.618725 |
| progressive bowel obstruction | 0.651874 |
| normal bowel function | 0.623449 |
| bowel obstruction | 0.807553 |
| Support Care Cancer | 0.590223 |
| acute diarrhea | 0.731833 |
| traveler’s diarrhea | 0.692746 |
| regimen-related diarrhea | 0.681582 |
| small bowel | 0.642547 |
| somatostatin analog octreotide | 0.636325 |
| depot octreotide | 0.600959 |
|
| chemotherapy-induced diarrhea | 0.813859 |
| malignant bowel obstruction | 0.739577 |
| cancer care | 0.622581 |
| cancer treatment-induced diarrhea | 0.733195 |
| severe diarrhea | 0.723383 |
| irritable bowel syndrome | 0.602845 |
| patients | 0.752157 |
| Clin Oncol | 0.637052 |
| cancer patients | 0.616135 |
| radiation-induced diarrhea | 0.788656 |
| neurogenic bowel dysfunction | 0.61585 |
| diarrhea | 0.944656 |
| inflammatory bowel disease | 0.603068 |
| bone marrow | 0.600992 |
| gastrostomy tube | 0.601159 |
| Nutr Clin Pract | 0.61137 |
| pelvic radiation-induced diarrhea | 0.726181 |
| octreotide | 0.694845 |
| extraluminal bowel lesions | 0.625405 |
| Delayed diarrhea | 0.692341 |
| fecal impaction | 0.682249 |
| et al. | 0.624888 |
| Subcutaneous octreotide | 0.602593 |
|
CLICK HERE |
| 1502 |
National Cancer Institute |
Html |
null |
Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas. |
|
|
CLICK HERE |
| 1521 |
National Cancer Institute |
Html |
en |
Cervical Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of cervical cancer. |
| IVA cervical cancer | 0.494515 |
| cervical cancer spreads | 0.502418 |
| body | 0.528161 |
| type | 0.484435 |
| Early cervical cancer | 0.515203 |
| PDQ cancer information | 0.510772 |
| clinical trial search | 0.530123 |
| clinical trials | 0.780834 |
| cancer information summary | 0.492424 |
| clinical trial | 0.63691 |
| IA cervical cancer | 0.494652 |
| vagina | 0.476362 |
| cervical cancer | 0.932453 |
| cervical tissue | 0.475608 |
| NCI PDQ cancer | 0.471306 |
| malignant tumor cells | 0.469474 |
| Treatment Option Overview | 0.483839 |
| lymph nodes | 0.584318 |
| radiation therapy | 0.643883 |
| Cervical Cancer Screening | 0.51612 |
| General information | 0.472784 |
| general cancer information | 0.468618 |
| treatment | 0.635154 |
| abnormal cells | 0.496903 |
| cervical cone biopsy | 0.469689 |
|
| cervical canal | 0.468388 |
| NCI-supported cancer | 0.488984 |
| cancer cells | 0.615466 |
| Cancer Information Service | 0.469545 |
| specific cancer cells | 0.475327 |
| Option Overview section | 0.476093 |
| IIA cervical cancer | 0.495532 |
| Recurrent cervical cancer | 0.57997 |
| treatment clinical trials | 0.483221 |
| cervical cancer stage | 0.518375 |
| National Cancer Institute | 0.533825 |
| cervix | 0.572702 |
| new treatment | 0.480833 |
| Cervical Cancer Prevention | 0.516533 |
| IVB cervical cancer | 0.494429 |
| procedure | 0.476082 |
| cancer clinical trials | 0.543686 |
| stage | 0.613195 |
| tumor | 0.505161 |
| cancer information summaries | 0.471295 |
| pelvic wall | 0.470332 |
| internal radiation therapy | 0.527167 |
| Cervical Cancer Treatment | 0.509501 |
| cancer | 0.952499 |
|
CLICK HERE |
| 1566 |
National Cancer Institute |
Html |
en |
Lung Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for lung cancer. |
| cancer treatment | 0.392038 |
| cancer screening methods | 0.488117 |
| lung cancer screening | 0.581106 |
| sputum cytology | 0.454434 |
| helical CT screening | 0.431007 |
| following PDQ summaries | 0.451695 |
| PDQ cancer information | 0.634342 |
| lung cancer | 0.990038 |
| clinical trials | 0.54732 |
| early-stage lung cancer | 0.49565 |
| Lung Screening Trial | 0.507741 |
| test result | 0.457525 |
| cancer information summary | 0.516813 |
| clinical trial | 0.403293 |
| small cell lung | 0.453619 |
| left lung | 0.419389 |
| breast cancer prevention | 0.412831 |
| diagnostic tests | 0.395868 |
| latest published information | 0.391467 |
| chest x-rays | 0.422818 |
| NCI’s PDQ | 0.406959 |
| cancer symptoms | 0.405957 |
| NCI PDQ cancer | 0.483096 |
| PDQ Screening | 0.452902 |
|
| low-dose helical CT | 0.462904 |
| Lung Cancer Prevention | 0.505332 |
| right lung | 0.42299 |
| cancer cells | 0.390233 |
| following screening tests | 0.445615 |
| spiral CT scans | 0.438882 |
| Cancer Information Service | 0.430519 |
| Prevention Editorial Board | 0.438477 |
| National Cancer Institute | 0.525164 |
| Cancer Screening Overview | 0.474654 |
| PDQ documents | 0.398876 |
| cancer death | 0.395593 |
| new treatment | 0.3913 |
| Cancer screening trials | 0.493779 |
| Cancer Care page | 0.417222 |
| PDQ database | 0.403172 |
| Low-dose spiral CT | 0.541598 |
| non-small cell lung | 0.454698 |
| PDQ summary | 0.523845 |
| cell lung cancer | 0.537709 |
| cancer information summaries | 0.438235 |
| comprehensive cancer information | 0.437914 |
| non-skin cancer | 0.39574 |
| chest x-ray | 0.418575 |
|
CLICK HERE |
| 1604 |
National Cancer Institute |
Html |
en |
Bladder and Other Urothelial Cancers Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for bladder cancer. |
| red blood cells | 0.494369 |
| cancer treatment | 0.489394 |
| bladder cancers | 0.541229 |
| urine | 0.494083 |
| ongoing clinical trials | 0.492966 |
| bladder urothelium | 0.575205 |
| following PDQ summaries | 0.556519 |
| Transitional cell carcinoma | 0.483769 |
| PDQ cancer information | 0.750577 |
| cancer increases | 0.491939 |
| false-negative test result | 0.489029 |
| bladder cancer | 0.812624 |
| clinical trials | 0.684635 |
| test result | 0.523443 |
| special test strip | 0.489962 |
| cancer information summary | 0.626401 |
| clinical trial | 0.502183 |
| breast cancer prevention | 0.514992 |
| false-positive test result | 0.488801 |
| cancer patients | 0.484495 |
| latest published information | 0.497666 |
| NCI’s PDQ | 0.51339 |
| cancer symptoms | 0.50531 |
| NCI PDQ cancer | 0.589485 |
|
| tests | 0.518118 |
| Squamous cell carcinoma | 0.486084 |
| PDQ Screening | 0.538371 |
| screening tests | 0.491835 |
| Cancer Information Service | 0.53331 |
| urothelial cancers | 0.536876 |
| PDQ Bladder | 0.571685 |
| Prevention Editorial Board | 0.549647 |
| treatment clinical trials | 0.491831 |
| National Cancer Institute | 0.634201 |
| PDQ documents | 0.50321 |
| cell carcinoma | 0.486793 |
| new treatment | 0.498073 |
| Cancer screening trials | 0.570719 |
| Cancer Care page | 0.519283 |
| PDQ database | 0.508182 |
| risk factor | 0.512484 |
| PDQ summary | 0.54439 |
| cells | 0.496479 |
| cancer information summaries | 0.541898 |
| comprehensive cancer information | 0.541535 |
| renal pelvis | 0.488981 |
| cancer | 0.961972 |
| Urothelial Cancers Screening | 0.519534 |
|
CLICK HERE |
| 1723 |
National Cancer Institute |
Html |
en |
Cell Phones and Cancer Risk |
A fact sheet that outlines the available evidence regarding use of cellular/mobile telephones and cancer risk. |
| study participants | 0.44259 |
| Self-reported cell phone | 0.407518 |
| past cell phone | 0.400866 |
| cell phone calls | 0.471967 |
| interphone study | 0.417191 |
| cell phone subscribers | 0.456865 |
| brain glucose metabolism | 0.405692 |
| brain tumors | 0.529155 |
| case-control study | 0.507596 |
| typical cell phone | 0.408953 |
| radiofrequency electromagnetic radiation | 0.493663 |
| radiofrequency energy exposure | 0.501417 |
| cell phone service | 0.411175 |
| radiofrequency energy | 0.823507 |
| brain cancer | 0.549627 |
| cell phone exposure | 0.408273 |
| mobile phone radiation | 0.402738 |
| cell phone base | 0.419397 |
| mobile phone | 0.45428 |
| specific absorption rate | 0.399693 |
| GSM mobile phone | 0.393442 |
| glucose metabolism | 0.4091 |
| Brain cancer incidence | 0.408493 |
| brain tumor incidence | 0.393633 |
| cell phone user | 0.438311 |
|
| study | 0.591826 |
| cohort study | 0.434065 |
| United States | 0.44975 |
| epidemiologic studies | 0.488267 |
| brain tumor risk | 0.390841 |
| cell phone | 0.960278 |
| cell phone technology | 0.436997 |
| National Cancer Institute | 0.439672 |
| long-term cell phone | 0.404741 |
| cell phones | 0.77677 |
| international case-control study | 0.404344 |
| prospective cohort study | 0.39373 |
| brain tumor | 0.434845 |
| brain cancer risk | 0.419878 |
| brain | 0.559028 |
| regular cell phone | 0.406823 |
| non-ionizing radiation | 0.395758 |
| cell phone radiofrequency | 0.472899 |
| cell phone users | 0.536299 |
| cell phone records | 0.414439 |
| et al | 0.586681 |
| cancer risk | 0.424868 |
| cancer | 0.54982 |
| risk | 0.454009 |
|
CLICK HERE |
| 1803 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de colon (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de colon. |
| Surgical Adjuvant Breast | 0.408847 |
| adjuvant chemotherapy | 0.410347 |
| non-metastatic colon | 0.414428 |
| Adults With Colorectal | 0.413355 |
| stage t4 colon | 0.415683 |
| locally advanced colon | 0.41442 |
| National Comprehensive Cancer | 0.414021 |
| American Society | 0.415077 |
| Study Group | 0.41129 |
| ensayo cancer | 0.415058 |
| Cancer Res | 0.41418 |
| Nelson H | 0.408583 |
| Radiat Oncol Biol | 0.414458 |
| colorectal cancer | 0.940744 |
| adjuvant therapy | 0.414593 |
| Natl Cancer Inst | 0.446315 |
| after curative resection | 0.408289 |
| with resected colon | 0.417545 |
| oxaliplatino capecitabina | 0.40883 |
| nonpolyposis colorectal carcinoma | 0.413444 |
| patients with | 0.47987 |
| Clinical Oncology | 0.42334 |
| colon nombre | 0.415112 |
| laparoscopic colon surgery | 0.427077 |
| CLA vs | 0.408768 |
|
| b2 colon cancer | 0.44357 |
| Dis Colon Rectum | 0.558033 |
| following laparoscopic-assisted | 0.410031 |
| Localized colon | 0.415631 |
| clinical outcomes | 0.414174 |
| 5-fu irinotecán | 0.410365 |
| Hereditary Cancer Syndromes | 0.413975 |
| patients with stage | 0.419991 |
| conventional colorectal resections | 0.419013 |
| Cancer Prevention Study | 0.415267 |
| colon cancer | 0.765585 |
| colon tumors | 0.415991 |
| Clin Oncol | 0.64523 |
| Oncol Biol Phys | 0.414687 |
| colorectal carcinoma | 0.429559 |
| 5-fu oxaliplatino | 0.41833 |
| estadio iii | 0.410102 |
| high-risk colon carcinoma | 0.415916 |
| surgical adjuvant | 0.409066 |
| American Joint Committee | 0.411047 |
| with colorectal cancer | 0.469671 |
| Colon Cancer Trials | 0.426531 |
| National Surgical Adjuvant | 0.40852 |
| Clinical Oncology colorectal | 0.413685 |
|
CLICK HERE |
| 1859 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de hipofaringe (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de hipofaringe. |
| Neck Cancer Cooperative | 0.13741 |
| pharyngeal cancers | 0.150792 |
| Pfister DG | 0.13468 |
| pyriform sinus treated | 0.135606 |
| Cancer Res | 0.206838 |
| Radiat Oncol Biol | 0.237454 |
| DeVita VT Jr | 0.131516 |
| pyriform sinus | 0.18629 |
| Natl Cancer Inst | 0.207961 |
| radiation therapy | 0.254373 |
| Head Neck Surg | 0.418544 |
| carcinoma treated with | 0.123784 |
| squamous carcinoma | 0.207808 |
| with surgery | 0.155955 |
| Mendenhall WM | 0.309662 |
| Head Neck | 0.426668 |
| estadio iv | 0.131056 |
| neck squamous | 0.149286 |
| Parsons JT | 0.126343 |
| radioterapia preoperatoria versus | 0.132896 |
| sinus treated with | 0.147408 |
| treated with surgery | 0.145993 |
| radioterapia posoperatoria | 0.168742 |
| Oral Oncol | 0.128712 |
| Hendrickson FR | 0.131539 |
|
| treatment based | 0.121981 |
| Otolaryngol Head Neck | 0.206433 |
| hypopharyngeal carcinomas | 0.157978 |
| radiotherapy with | 0.12894 |
| with poor prognosis | 0.124956 |
| hypopharyngeal squamous | 0.152628 |
| Spindle cell carcinoma | 0.12283 |
| Clin Oncol | 0.138573 |
| combined with neck | 0.126143 |
| Oncol Biol Phys | 0.243047 |
| combining radiotherapy with | 0.126277 |
| estadio iii | 0.184936 |
| radiotherapy with surgery | 0.128843 |
| Treat Options Oncol | 0.123145 |
| radioterapia adyuvante posoperatoria | 0.177283 |
| European Organization | 0.12179 |
| neck cancer | 0.973991 |
| undifferentiated carcinomas | 0.126856 |
| quimioterapia neoadyuvante | 0.630349 |
| locally advanced | 0.131399 |
| Hansen O | 0.125257 |
| induction chemotherapy | 0.134893 |
| neck carcinoma | 0.172184 |
| squamous cell carcinoma | 0.867141 |
|
CLICK HERE |
| 1887 |
National Cancer Institute |
Html |
es |
Tratamiento del carcinoma de células de Merkel (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del carcinoma de células de Merkel. |
| Cutan Pathol | 0.403221 |
| skin cancer | 0.402076 |
| critical review with | 0.401107 |
| cell carcinoma showing | 0.404318 |
| review with guidelines | 0.401112 |
| Australian Merkel cell | 0.404544 |
| Distinct merkel cell | 0.404503 |
| Am Acad Dermatol | 0.404485 |
| cell polyomavirus dna | 0.402185 |
| Curr Opin Oncol | 0.401201 |
| Cell Carcinoma Information | 0.404476 |
| 7th ed | 0.401399 |
| Rockville Merkel Cell | 0.404613 |
| ganglios linfáticos centinela | 0.405335 |
| SEER Program | 0.402412 |
| cell carcinoma tumors | 0.407605 |
| Coit DG | 0.402335 |
| into merkel cell | 0.405013 |
| Seattle Cancer Care | 0.401199 |
| Cancer Care Alliance | 0.401228 |
| Natl Cancer Inst | 0.40149 |
| Merkel tumours | 0.402858 |
| patients with merkel | 0.422467 |
| with cutaneous merkel-cell | 0.401294 |
| Arch Dermatol | 0.401934 |
|
| cutaneous merkel-cell carcinoma | 0.404932 |
| with merkel cell | 0.435163 |
| Invest Dermatol | 0.401806 |
| neuroendocrine-merkel cell carcinoma | 0.404323 |
| Cancer Staging Manual | 0.402011 |
| patients from | 0.401403 |
| Surg Oncol | 0.411261 |
| Nghiem P | 0.404669 |
| New York | 0.401702 |
| merkel cell carcinoma | 0.998942 |
| specimens from patients | 0.401221 |
| Clin Oncol | 0.41408 |
| Dermatol Surg | 0.40166 |
| CCM recién | 0.401912 |
| Carcinoma Group | 0.402481 |
| cell carcinoma demographics | 0.418051 |
| primary merkel | 0.405524 |
| Trabecular carcinoma | 0.402756 |
| American Joint Committee | 0.401365 |
| merkel cell polyomavirus | 0.432273 |
| cell carcinoma after | 0.40431 |
| cell polyomavirus infection | 0.402124 |
| merkel-cell carcinoma | 0.40673 |
| from patients with | 0.402629 |
|
CLICK HERE |
| 3575 |
National Cancer Institute |
Html |
en |
NCI’s Role in Cancer Research |
When people think about cancer research, they may envision men and women in lab coats, carefully dripping substances into test tubes or peering thoughtfully into microscopes. Of course, those things do happen in biomedical research. But they are just one small part of a much larger research landscape. |
| larger research landscape | 0.406002 |
| research projects | 0.473958 |
| ongoing research projects | 0.366171 |
| NCI’s research | 0.415082 |
| clinical trials | 0.909263 |
| translational research | 0.434177 |
| Cancer Informatics Program | 0.357576 |
| NCI leadership | 0.366577 |
| NCI funding | 0.344193 |
| NCI’s budget | 0.341097 |
| basic research questions | 0.406498 |
| specific research areas | 0.376759 |
| late-phase clinical trials | 0.337365 |
| cancer research study | 0.479905 |
| cancer research studies | 0.541646 |
| private sector | 0.396556 |
| NCI’s divisions | 0.382718 |
| NCI’s mission | 0.342763 |
| NCI | 0.563137 |
| clinical research | 0.358682 |
| population-based research | 0.407311 |
| NCI intramural program | 0.395461 |
| NCI senior leadership | 0.384992 |
| cancer research continuum | 0.462835 |
| advisory boards | 0.398662 |
|
| new cancer treatments | 0.407593 |
| implementation research | 0.334824 |
| cancer cells | 0.456417 |
| pediatric cancer survivors | 0.362759 |
| cancer research | 0.981446 |
| new cancer research | 0.494493 |
| Later-phase clinical trials | 0.343846 |
| NCI review | 0.341394 |
| earlier research | 0.344026 |
| different cancer types | 0.386961 |
| NCI conducts | 0.339869 |
| cancer outcomes | 0.342815 |
| NCI program offices | 0.431082 |
| health care | 0.339118 |
| cancer researchers | 0.448005 |
| new treatment | 0.465207 |
| NCI staff | 0.45834 |
| important research projects | 0.386667 |
| Cancer Genome Atlas | 0.377483 |
| biomedical research | 0.393005 |
| cancer risk | 0.371733 |
| research programs | 0.395973 |
| cancer biology | 0.366782 |
| basic research | 0.65541 |
|
CLICK HERE |